Targeted Protein Degradation: The Drug Discovery Approach That Could Make Disease-Causing Proteins Disappear

For decades, the challenge in drug discovery was finding the right way to block a disease-causing protein. But what if blocking it was the wrong objective altogether?

What if, instead of trying to keep a malfunctioning protein under control, a drug could simply tell the cell to remove it?

Targeted protein degradation (TPD) takes this approach. Rather than blocking a disease-associated protein, it tags that protein for destruction using the cell’s own waste-disposal system. This opens the door to disease-causing proteins that older drugs could not easily target.

This article walks through how targeted protein degradation works, from its earliest scientific milestones to the technologies being developed today. It is the first in a series, with the articles that follow taking a closer look at the patent landscape surrounding TPD and where the field is likely headed next.

What Is a Protein and Why Would a Cell Need to Destroy One?

Proteins are like working machinery in our body cells. They carry out thousands of functions from transmitting chemical signals, transporting materials, repairing tissues, regulating gene expression, as well as facilitating cell growth and division.

However, protein molecules cannot last long in the cell. They can become damaged, misfolded, overproduced, harmful, and involved in disease. If such unwanted proteins accumulate it would upset the normal cellular function. Therefore, cells have overcome this problem by having their own highly organized waste-disposal and recycling systems – the proteasome, the lysosome, and the autophagy-lysosome pathway.

Think of them as different recycling centers operating inside and outside the cell, each built for a different kind of junk.

TPD is what happens when drug discovery learns to use these systems on purpose.

What Is Targeted Protein Degradation?

Targeted protein degradation (TPD) refers to a drug discovery approach that allows researchers to selectively destroy a specific protein from a cell. The molecular mechanism of TPD has been mostly inspired by the major ubiquitin-proteasome system (UPS), which is a part of the cell’s natural mechanisms for removing proteins. In short:

• A degrader brings a disease-related protein close to an E3 ubiquitin ligase.
• The E3 ligase tags the protein with ubiquitin, a “destroy me” label.
• The proteasome, a molecular shredder, recognizes the tag and breaks down the protein.

Cells have been doing this on their own for billions of years, clearing out damaged or unneeded proteins as routine maintenance. TPD’s real innovation is not protein destruction itself, it’s directing the cell to select a specific protein that the researcher’s choose and route it towards cell degradation machinery that already exists.

Timeline of Targeted Protein Degradation

2001: The concept of a PROTAC is first proposed in scientific literature, an early demonstration that a molecule could be built to bring a target protein and the cell’s disposal machinery together on purpose.

2000s-2010s: Researchers came to recognize molecular glues as a distinct mechanism of action, one that, in retrospect, explained how older drugs like thalidomide and its derivatives, lenalidomide and pomalidomide, had actually been working all along. These drugs had already become long-standing, approved treatments for multiple myeloma, which makes them the field’s earliest clinically successful degraders, even though the term “molecular glue” would not gain wide use until years later.

Mid-2010s: PROTAC technology begins to mature at a rapid pace. Firms like Arvinas, Kymera Therapeutics and C4 Therapeutics develop whole drug-discovery platforms around it, while academic labs work on finding new types of E3 ligase that could be used beyond the few that are already known.

Late 2010s–early 2020s: Next-generation approaches begin to emerge, such as LYTACs, AUTACs, and related technologies. These approaches extend the core idea of TPD beyond the proteasome and in some cases, beyond the cell itself, opening up new categories of druggable targets and new patentable territory.

May 2026: A Major Milestone for TPD: The FDA approves vepdegestrant, an oral PROTAC for a form of metastatic breast cancer, the first PROTAC ever to reach approval, roughly 25 years after the concept was first proposed. The question is no longer simply: can a PROTAC become an approved drug?

The focus is shifting away from that question and toward a more interesting one: which targets, molecular designs, E3 ligases, and degrader technologies will go on to produce the next generation of successful medicines?

Today and beyond: With PROTACs now clinically and commercially validated, attention is turning to what comes next, new E3 ligases, emerging modalities such as DACs, and applications that reach well beyond oncology into neurodegeneration, infectious disease, and inflammatory conditions.

What Challenge Does Targeted Protein Degradation Solve?

Conventional drugs generally work by binding to a suitable protein and change its activity. TPD takes a different route. Rather than trying to find the right place to block the protein, a degrader brings the protein to the cell’s natural disposal machinery and triggers its removal.

This reframes the entire problem. A protein does not need a druggable pocket to be degraded; it just needs to be brought close enough to the right piece of cellular machinery. This shift is what allows TPD to reach targets that were previously considered difficult or even impossible to address with conventional drug discovery.

This has made TPD particularly attractive in oncology, where many important disease drivers have historically been difficult to drug. But the opportunity extends beyond cancer. Potential applications are also being explored in:

• Neurodegenerative diseases
• Immune and inflammatory disorders
• Infectious diseases
• Genetic and rare diseases

TPD vs Conventional Technology

Traditional drug discovery asks: How can we stop this protein?

TPD asks: How can we make the cell remove this protein?

Traditional drugs most often work by binding a protein and blocking its function and in many cases, the drug has to stay attached to keep working. Degraders work differently. Their job is not to block the protein; it’s to trigger its removal. Once the degradation machinery has been recruited and the target is marked for destruction, the degrader itself can move on and set up another degradation event elsewhere.

This is often described as a shift from occupancy-driven pharmacology to event-driven pharmacology.

The distinction matters because TPD is not simply another way to inhibit the same old proteins, it creates the possibility of removing the protein altogether, which is valuable exactly where conventional inhibition struggles.

This does not mean every difficult-to-drug target automatically becomes tractable. Degradation still requires suitable target engagement, productive complex formation, compatible cellular machinery, and an acceptable drug profile.

TPD is no longer just a PROTAC story. What began with the recruitment of the ubiquitin-proteasome system has expanded into a much broader technological landscape. Researchers are now exploring different ways to control the fate of proteins using the proteasome, lysosome, autophagy pathways, antibodies, light, engineered tags, and other forms of induced proximity.

These technologies are not simply different versions of the same idea. They represent different solutions to a central challenge: how do you remove the right biological target using the right cellular machinery?

How It Actually Works: The Mechanism Behind Degradation

Once a degrader finds its target, the real work begins. The cell already has systems for getting rid of unwanted proteins; TPD essentially learns how to direct a specific protein into one of them. Most approaches use one of three routes: the proteasome, the lysosome, or autophagy.

The first route is the ubiquitin-proteasome system (UPS), used by approaches such as PROTACs and molecular glues. A degrader brings the target protein close to an E3 ubiquitin ligase, which attaches ubiquitin tags to it. The tagged protein is then sent to the proteasome, where it is broken down. Once this happens, the degrader can be released and used again to target another copy.

The second route is the lysosome. Technologies such as LYTACs, AbTACs, KineTACs, and DENTACs use cell-surface receptors to bring extracellular or membrane-associated proteins into the cell and route them to the lysosome for destruction.

The third route is autophagy, used by approaches including AUTACs, ATTECs, and AUTOTACs. Rather than sending individual proteins directly to the proteasome, these systems use autophagy to deliver larger proteins, complexes, or aggregates to the lysosome.

Each route depends on distinct biological machinery and mechanisms of action, which is exactly why each one opens a different kind of IP opportunity.

Major Targeted Protein Degradation and Related Proximity Technologies

TPD is not a single technology. It is a broader group of approaches that use the cell’s own systems to remove or control unwanted proteins. The main difference between them is which cellular pathway they use, what they bring together, and what type of protein they can reach.

Proteasome-Based TPD

1. PROTACs

PROTACs are one of the most prominent approaches in targeted protein degradation. They are single molecules with two binding ends joined by a linker:

• One end binds the disease protein.
• The other end binds an E3 ubiquitin
• The linker holds them in the right orientation so the E3 can tag the disease protein.

After tagging, the PROTAC can dissociate and repeat the process on another target molecule. In simple terms, one end finds the protein and the other brings in the machinery needed to remove it.

2. Molecular Glues

Molecular glues take a different approach. Instead of having two clearly separated binding ends like a PROTAC, they are generally single small molecules that act like an adhesive. They help bring a target protein into contact with a degradation-related protein, creating an interaction that allows the cellular machinery to recognize and remove the target.

3. SNIPERs: Specific and Non-genetic IAP-dependent Protein Erasers

Structurally similar to a PROTAC, a SNIPER is a bifunctional molecule with one end that grabs the target protein and another that recruits an E3 ligase, but instead of the usual CRBN or VHL, it hijacks a different family of proteins called IAPs (inhibitor of apoptosis proteins). This gives researchers an alternative disposal route when the more commonly used ligases are not a good fit for a given target.

4. HyT: Hydrophobic Tagging

Hydrophobic tagging takes a different path entirely, as it does not need E3 ligase. It attaches a hydrophobic group to a ligand that binds the target protein, then the cell’s own quality-control system does the rest.

Once that hydrophobic patch is exposed, it essentially fools the cell into treating the protein like it’s misfolded, junk that needs to go, triggering the same disposal machinery the cell would normally use to clear out damaged proteins.

The design is refreshingly simple compared to a classical PROTAC:

• A ligand for the protein of interest.
• A linker.
• A hydrophobic tag, with no separate E3 ligase component required.

It’s best thought of as sitting in its own category: an alternative, proteasome-directed route to degradation that does not play by the usual PROTAC rules.

5. CIDEs: Chemical Inducers of Degradation

CIDEs are chemical approaches designed to trigger protein degradation without necessarily following the classic two-ended PROTAC structure. They represent another way of using small molecules to direct selected proteins toward cellular degradation machinery.

Some CIDE designs can also be combined with larger targeting components, such as antibodies, to help direct degradation toward particular cells or tissues.

6. Peptide: Based PROTACs/P-PROTACs

P-PROTACs use peptides or peptide-like molecules as part of the target-recognition system. They follow the same basic induced-proximity idea as PROTACs but can provide access to protein surfaces that are difficult to target with conventional small molecules.

Their potential advantages come with challenges such as cell penetration, proteolytic stability, and pharmacokinetics.

7. bioPROTACs

bioPROTACs replace conventional small-molecule components with biological binding elements, such as engineered proteins or nanobodies. These components can be designed to recognize a target and bring it together with protein-degradation machinery.

Because they are generally genetically encoded and produced inside cells, bioPROTACs are used mainly as research and target-validation tools rather than conventional drugs.

8. Ubiquibodies

Ubiquibodies use an antibody derived binding component connected to protein-degradation machinery. The antibody like part recognizes the target protein, while the attached machinery helps direct it toward degradation. They are closely related to bioPROTACs but use a different biologic architecture to achieve the same overall goal: bringing the target and degradation machinery together.

The limitations of proteasome-based degradation led researchers to ask a bigger question: why should targeted degradation be restricted to proteins inside the cell? Then the lysosome and autophagy pathways entered the picture, the potential target space began to expand beyond intracellular proteins to cell-surface proteins, extracellular proteins, and even larger protein aggregates.

Lysosome and Autophagy-Based TPD

The proteasome is not the only system cells use to dispose of unwanted material. Some important disease-related proteins are found on the cell surface or outside the cell, while larger proteins and protein assemblies may be better suited to other cleanup pathways. This led researchers to explore the lysosome and autophagy systems as additional routes for targeted degradation.

9. LYTACs: Lysosome-Targeting Chimeras

LYTACs were developed to address targets that conventional PROTACs cannot easily reach, particularly proteins on the cell surface or outside the cell.

They target proteins that sit on the outside of a cell or float around entirely outside, places the usual disposal system cannot reach. A LYTAC tags these outside proteins and drags them into a different disposal unit, the lysosome, essentially the cell’s version of a recycling center.

10. AbTACs: Antibody-Based PROTACs

AbTACs share the core idea of induced proximity with PROTACs, but they are structurally and mechanistically distinct. Instead of a small molecule, AbTACs use bispecific antibodies to connect a cell-surface target with a receptor or degradation-related system that can help pull it into the cell. Once both grips are in place, the whole complex gets pulled inside the cell, where the lysosome, not the usual proteasome, takes over and breaks it down.

11. GlueTACs

GlueTACs are a newer hybrid approach that combines the induced-proximity concept of molecular glues with antibody-based targeting. They are designed to bind selected cell surface proteins, bring them into the cell, and direct them to the lysosome for degradation.

12. KineTACs: Cytokine Receptor-Targeting Chimeras

KineTACs are designed to remove proteins from the cell surface. They majorly use cytokine receptor pathways to bring the target protein into the cell and direct it to the lysosome for degradation. This gives researchers another alternative to conventional PROTACs, which generally target intracellular proteins, and expands targeted degradation to cell-surface proteins.

13. PROTABs: Proteolysis-Targeting Antibodies

PROTABs are antibody-based degraders that are designed to remove selected proteins from the cell surface. They use antibodies to bind the target protein and bring it inside the cell. Once it is inside, the target is directed to the lysosome, where it is degraded. This approach adds another antibody-based approach to the targeted protein degradation landscape and helps address cell surface targets that are difficult to reach with conventional PROTACs.

14. DENTACs: Dendronized DNA Chimeras

DENTACs take a different approach by using a DNA-based structure to recognize extracellular targets instead of an antibody. Once the target is taken into the cell, it is directed to the lysosome for degradation, similar to LYTACs and AbTACs. The main difference is that DENTACs use a DNA-based system to recognize and bring the target inside the cell, offering another way to direct extracellular proteins to the lysosome.

15. IFLD: Integrin-Facilitated Lysosomal Degradation

IFLD uses integrins which are receptors that are found on the cell surface. It helps bring extracellular or membrane-bound proteins into the cell. Once inside the cell the target is directed to the lysosome for degradation. This provides another way to target proteins that may be difficult to reach through conventional lysosome-based approaches.

16. ROTACs: R-Spondin Chimeras

ROTACs use the biology of R-spondin, a natural signaling system involved in regulating certain cell-surface receptors. Researchers adapt this system to help direct selected membrane proteins toward degradation. The approach provides another way to remove cell-surface proteins by using a receptor pathway that the cell already knows how to internalize.

17. AUTACs: Autophagy-Targeting Chimeras

If the proteasome is a shredder for individual items, autophagy is more like a bulk-cleanup system. Some cellular junk is too big or too clumped-together for the usual disposal system to break down, think large protein aggregates rather than a single stray protein. AUTACs route these bulkier targets to autophagy, a separate cellular process built specifically for clearing out larger debris.

18. ATTECs: Autophagosome-Tethering Compounds

ATTECs are another approach that uses the cell’s natural autophagy pathway to remove unwanted proteins. They work by directly connecting the target protein to the autophagy machinery, which helps the cell capture the target and transport it to the lysosome for degradation. Unlike conventional PROTACs, which typically rely on the ubiquitin–proteasome system, ATTECs use autophagy as the route for protein removal. This makes them useful for exploring the degradation of targets that may be difficult to address with conventional PROTACs.

19. AUTOTACs: Autophagy-Targeting Chimeras

AUTOTACs are a newer autophagy-based approach that works through a different mechanism than AUTACs and ATTECs. AUTOTACs are bifunctional molecules, similar in concept to PROTACs, that connect the target protein to a protein called p62, which helps direct it into the cell’s autophagy system for removal.

20. SignalTACs: Signal-Mediated Lysosome-Targeting Chimeras

SignalTACs use cellular trafficking signals to guide selected proteins toward the lysosomal degradation pathway. Rather than depending on the receptor-based strategies used by some other lysosome-directed technologies, they use the cell’s own transport signals. This makes SignalTACs another emerging approach for directing target proteins toward lysosomal disposal.

21. CMA-Based Degraders: Chaperone-Mediated Autophagy Degraders

CMA-based degraders use the cell’s natural chaperone-mediated autophagy pathway to remove specific intracellular proteins. In this process, cellular chaperone proteins recognize the target protein and help deliver it directly into the lysosome, where it is broken down. Unlike other autophagy-based approaches, such as AUTACs, ATTECs, and AUTOTACs, CMA-based degradation does not require the formation of an autophagosome. Instead, the target protein is transported directly to the lysosome for degradation.

Specialized / Conditional Degradation

The next advance in TPD was not about finding more ways to degrade proteins, it was about gaining control over where, when, and in which cells degradation happens.

22. DACs: Degrader-Antibody Conjugates

DACs borrow an idea from a different corner of medicine: antibody-drug conjugates. The concept is simple enough: take a degrader, often a PROTAC, and attach it to an antibody. What you end up with is a single molecule doing two distinct jobs. The antibody’s role is delivery, finding the right cells or tissue and binding to them. Once it arrives, the attached degrader takes over and does the actual work of clearing out the target protein. As an emerging modality, DACs could create new opportunities around targeted delivery, therapeutic selectivity, and IP protection.

23. Opto-PROTACs and Other Photo-Controlled Degraders

Photo-controlled degraders use light to regulate protein degradation with spatial and temporal precision. The light-responsive component may be a photocage, photoswitchable linker, photoresponsive target ligand, or photoresponsive E3-ligase ligand. This group includes Opto-PROTACs, PhotoPROTACs, Photocaged PROTACs, Photoswitchable PROTACs, Photocaged molecular glues, Near-infrared-responsive degraders and Two-photon-responsive degraders

These systems are mainly research and proof-of-concept platforms for controlling exactly when and where a protein is degraded.

24. TRIM-Away and TRIMbody-Away

TRIM-Away uses antibodies to bring a target protein to TRIM21, a cellular protein degradation system. Once recruited, the target can be marked for destruction and removed by the proteasome.

TRIMbody-Away follows a similar principle but uses smaller engineered binding proteins instead of a full antibody, making the approach useful for rapid protein depletion in research.

25. BacPROTACs

BacPROTACs apply the targeted degradation concept to bacteria. Instead of using the degradation machinery found in human cells, they direct selected bacterial proteins toward the bacterium’s own protein-degradation systems. This extends the induced-proximity approach into bacterial research and could eventually support the development of more targeted antimicrobial strategies.

Research and engineered degradation tools

Not every degradation technology is intended to become a medicine. Some of the most important tools in the field were designed to answer a more fundamental question first: what happens when this protein disappears?

26. dTAGs: Degradation Tags

dTAG is a widely used research tool rather than a treatment. Researchers add a small tag to the protein they want to study and then use a specially designed degrader that recognizes the tag and triggers the protein’s removal inside cells. This allows researchers to selectively remove a protein and observe how its absence affects the cell. As a result, dTAG has become a useful tool for studying protein function and evaluating potential drug targets, rather than being used as a treatment itself.

27. HaloPROTACs

HaloPROTACs work on a principle similar to dTAGs but use a different genetic tag called HaloTag. Researchers attach this tag to a protein of interest and then use a specially designed degrader to trigger its removal. Like dTAGs, HaloPROTACs are mainly research tools that help scientists study the function of specific proteins and understand the effects of their degradation.

28. NanoTACs: NanoLuc-Targeting PROTACs

NanoTACs are genetically encoded research tools that use a small NanoLuc tag to identify and target a protein for degradation. The tag also produces a measurable light signal, allowing researchers to track how quickly and effectively the tagged protein is degraded. This makes NanoTACs useful for studying protein degradation and measuring its effects in cells.

29. BromoTag

BromoTag is another tagging system designed to help researchers control the degradation of specific proteins in the laboratory. A protein is given a BromoTag, which can then be recognized by a specially designed small molecule that triggers its degradation. Like dTAGs and HaloPROTACs, BromoTag is primarily a research tool for studying protein function rather than a therapeutic approach.

30. AID: Auxin-Induced Degron

AID is one of the oldest tools in this category and was originally inspired by a protein-control system found in plants. Researchers attach a specific tag to a protein of interest and use a plant hormone called auxin to trigger the degradation. This gives researchers a simple on-off switch for removing a chosen protein and studying its function.

AID2 is an improved version of the system that uses an engineered tag and a synthetic auxin-like molecule. It allows researchers to trigger protein degradation more efficiently and with greater control.

31. SMASh: Small-Molecule-Assisted Shutoff

SMASh is a research tool which allows scientists to control the amount of a specific protein inside a cell. A regulatory tag is attached to the protein, and a small molecule is used to trigger its removal. This gives researchers a way to reduce or shut off the protein and study what happens when its levels change. Like any other tools in this category, SMASh is mainly used for research rather than as a treatment.

32. AdPROMs: Affinity-Directed Protein Missile

AdPROMs are research tools that combine a protein-binding component with the cell’s own degradation machinery. They are mainly used in the laboratory to test whether degrading a particular protein through a specific degradation pathway could be useful, before investing in the development of a small-molecule degrader.

33. ARMeD: Antibody RING-Mediated Destruction

ARMeD is a biologic-based approach that uses an antibody-like component to recognize a specific protein and bring it together with the cell’s protein-degradation machinery. Like AdPROMs and other engineered degradation tools, ARMeD is primarily used for research and target validation rather than as a direct therapeutic approach.

Related Technologies Beyond Targeted Protein Degradation

The TPD landscape also overlaps with a broader family of proximity-based technologies. These approaches use the same general principle, bringing biomolecules together on purpose, but not all of them degrade proteins. Distinguishing them from core TPD approaches helps clarify the actual scope of the field.

34. DUBTACs: Deubiquitinase-Targeting Chimeras

DUBTACs take the opposite approach to targeted protein degradation. Rather than helping the cell destroy a target protein, they recruit an enzyme called deubiquitinase (DUB) which removes molecular signals that normally mark proteins for degradation. This can help protect the target protein and increase its stability inside the cell.

As a result, DUBTACs are better described as a protein-stabilization technology rather than a true TPD modality. They are closely related to TPD because both use induced proximity to control the amount and fate of specific proteins.

35. RIBOTACs: Ribonuclease-Targeting Chimeras

RIBOTACs extend the induced-proximity concept beyond proteins entirely. They recruit ribonucleases to selected RNA molecules, resulting in targeted RNA degradation. Because the substrate here is RNA rather than protein, RIBOTACs are not technically a TPD modality, but they’re a useful demonstration of how far the same underlying logic can travel beyond where it started.

This is where the story becomes bigger than protein degradation itself. The field is expanding from protein destruction to something broader: programmable control over biological function. The same induced-proximity principle can potentially be used not only to eliminate proteins, but also to stabilize them, modify them, alter their interactions, or direct the degradation of entirely different biological molecules.

Emerging Technologies Beyond TPD

Several other approaches, including AceTAC, PhosTAC, PHIC, PHORC, HEMTAC, and CHAMP, also build on the principle of induced proximity but are not aimed at degrading proteins at all. Instead, they influence protein stability, activity, modification, or interactions, for example through phosphorylation, acetylation, or the recruitment of regulatory proteins. Because these approaches do not involve protein degradation, they fall under the broader category of proximity-based technologies but remain distinct from TPD.

Together, all of these approaches show that the field has outgrown its original premise. Induced proximity started as a way to remove unwanted proteins, and it’s increasingly being adapted to degrade, stabilize, modify, or otherwise control biological targets, whichever the situation actually calls for.

Where Targeted Protein Degradation Still Falls Short

TPD has opened the door to proteins that were difficult to target with conventional drug approaches, but the technology still faces several challenges.

• Selectivity: A degrader must only remove the specific target protein without causing side effects with other proteins and cellular processes. This is challenging to achieve, especially when the targeted proteins are present in many different tissues.
• Finding the right degradation machinery: Not every target can be easily connected to an E3 ligase, lysosomal receptor, or other cellular disposal system. The availability and activity of these pathways can also vary between cell types.
• Drug design: Degraders such as PROTACs can face added hurdles in clinical development as they are much larger and more complex than conventional small molecule drugs. As a result, selecting an optimal degrader means balancing several variables at once – target binding affinity, cellular uptake efficiency, metabolic stability, and degradation activity.

There are also practical questions around resistance, safety, and drug exposure. A target may become harder to degrade if the relevant degradation machinery is altered, while prolonged or excessive protein removal could potentially create unwanted biological effects.

Final Thoughts

After looking across the expanding TPD landscape, three things become clear.

First, PROTACs are only one part of a much larger degradation ecosystem. Different technologies are being developed because different targets require different cellular disposal pathways.

Second, none of the open challenges above are likely to be solved by a single breakthrough. They will be chipped away at from multiple directions at once, better E3 ligases, smarter linker chemistry, more precise delivery systems, which means the companies that solve even one piece well are positioning themselves at the center of where the field goes next.

Third, the competitive landscape will increasingly be shaped by more than drug candidates. E3 ligases, target binders, linker designs, delivery platforms, receptor systems, biological mechanisms, and emerging proximity technologies are all becoming important areas for innovation and IP strategy.

In other words, the TPD opportunity is not one technology or one market. It is an expanding technological ecosystem built around deliberately controlling the fate of biological molecules.

How Ingenious E-Brain Can Help

We are an international management consulting and research advisory firm supporting forward-looking companies. We help them identify:

• Where are the real IP opportunities?

Not every apparent gap in the patent landscape represents a genuine opportunity. We look across E3 ligase recruiters, linker chemistries, target classes, delivery technologies, and emerging degrader modalities to identify areas with meaningful IP potential.

• Who is actually competing in this space?

We help build a clearer picture of the competitive landscape by looking beyond companies with visible drug pipelines. By examining patent activity, scientific research, clinical development, strategic partnerships, licensing agreements, and technology-transfer activity, we identify the organizations actively shaping the field.

• Where is the field likely to go next?

We bring together scientific, technological, patent, regulatory, and deal-making signals to identify emerging directions and support better R&D and business development decisions.

The combination of deep technical knowledge with future-oriented strategy enables us to help our clients reduce their risks, keep ahead of the competition, and make more informed long-term decisions.

Talk to our seasoned IP experts by filling out the form below or emailing us at contact@iebrain.com.